Did you know...  That one in every six people on this globe suffers from a disease of poverty?  That ten million people die each year from diseases.

Slides:



Advertisements
Similar presentations
FamiliesUSA The Neglected Tropical Diseases
Advertisements

Ranbaxy Laboratories Limited Differential Pricing & Financing of Essential Drugs Experience with Generic drugs Cecile H Miles Head of Western Europe Division.
Neglected Tropical Diseases and Malaria: The need for mapping.
The Scientist: Ted Key Poverty Related to Health Issues.
Promoting patient-centred healthcare around the world Advancing the fight against counterfeit medicines Ms. Regina Kamoga IAPO Board Member, Country Manager,
10 FACTS ON NEGLECTED TROPICAL DISEASES Fact 1 More than 1 billion people are affected by one or more neglected tropical diseases (NTDs). They are named.
Famine and Disease in Africa
Penn’s Innovations and the Global Poor Facilitating Access to Medicines in Developing Countries Universities Allied for Essential Medicines 22 Mar 2006.
MIT Universities Allied for Essential Medicines. PIH/David Walton.
What role to universities play in biomedical research and development? In the US, most basic biomedical research is performed at universities and funded.
Designing Strategies for Neglected Disease Research Lecture 1A Amy Kapczynski UC Berkeley Law From MSF Campaign for Access to Essential Medicines, AccessNews.
Nathan Trayner 1,2 ; John Prensner 1,2 ; Heather Ames 1,2 ; Ashwin Vasan 1,2 1.MD Candidate, University of Michigan Medical School 2.Universities Allied.
Access to essential medicines of the future Bernard Pécoul Director, Campaign for Access to Essential Medicines Médecins Sans Frontières.
The Work of WHO in the South-East Asia Region The Work of WHO in the South-East Asia Region Biennial Report of the Regional Director 1 January
More on Generic Drugs Global Classrooms 2013 Rachel Hunkler.
Andrew Gray March 10, Poverty Basic nutrition and clean water Shelter Education Basic medical care (public health) Lack of access.
Drug Pricing in Canada Victoria Brown, Anureet Sohi, Lisa Weger SPHA 511.
Pharmaceuticals before and after TRIPS Sudip Chaudhuri Professor of Economics Indian Institute of Management Calcutta BRICS Workshop, Aalborg February,
IP for Scientists Universities Allied for Essential Medicines (UAEM) UC Berkeley.
Problems after Independence By 1980 most of Africa was free from European rule. However, many of the newly independent countries face many problems.
The Role of TNCs and AIDS drugs – “Lives before profits”? L.O.s 1.To define the terms: TNC, Generic, “Big Pharma”, ARVs, HAART, Tiered Pricing. 2.To describe.
EUROPEAN NETWORK FOR GLOBAL HEALTH TO EUROPEAN ALLIANCE AGAINST MALARIA Barcelona, 28 de febrero de 2007.
Access to Essential Medicines and Intellectual Property Rights in Developing Countries Rachel M. Cohen Access to Essential Medicines Campaign Doctors Without.
Universities Allied for Essential Medicine Central Michigan University Chapter Increasing Global Access to Medicine through Information Transfer and the.
Call to governments: Boost innovation for neglected diseases Bernard Pécoul Executive Director MSF meeting 8 June 2005.
La recherche avance, la vie progresse. MEDICINE AND HEALTH IN THE TROPICS Plenary Session 3 « The Pharmaceutical Industry’s R&D Drive and the issue of.
PATENTS AND HEALTH. A CASE STUDY OF THE UGANDAN CONTEXT. (PHA3 JULY 7 TH 2012 –CAPE TOWN, SOUTH AFRICA) MS. MARIAM AKIROR LLB (HONS) / DIP. SW / CPC. PROG.
1 Patents and Public Health Dr. Eric Noehrenberg Director International Trade and Market Policy, IFPMA WIPO Open Forum on the draft SPLT, Geneva, 3 March.
1 |1 | Key problems Neglected Tropical Diseases Hidden and silent : Key problems Complacency, lack of information and commitment Complacency, lack of information.
Neglected Tropical Diseases: Control & Research
Pricing and the Pharmaceutical Industry What’s Realistic? What’s Smart? What’s Right?
Essential Medicines and the University Challenge: Promoting Local Research for Global Impact For more information, please visit: UAEM home page:
MALARIA AND NEGLECTED TROPICAL DISEASES (NTDs): FINDINGS FROM THE 2012 G-FINDER REPORT.
MSF Access Campaign Started in 1999 Rooted in field experience Three Pillars: –Overcoming Barriers –Research and Development for Drugs for Neglected Diseases.
CABI product training Global Health Tom Corser. Global Health Agenda ● CABI publishing and product overview ● Live product demo of CAB Direct including.
Do Patents Make HIV/AIDS Medication Inaccessible to Patients in Sub-Saharan Africa? Abstract There has been debate surrounding the issue of patents and.
Alternative R&D Strategies for Drugs for Neglected Diseases: The Case & Possible Alternatives TACD IPR Meeting Washington Nov 1, 2002.
© IFPMA 2009WIPO Open-ended Forum on Proposed Development Agenda Projects - 13/10/2009 IFPMA views on the strategic use of information for sustainable.
Intellectual Property Rights and Pharmaceuticals (Case study- Novartis’s claim in India) Background note prepared for PHM Vic Internet Workshop.
Pricing and the Pharmaceutical Industry What’s Realistic? What’s Smart? What’s Right?
Treating MDR-TB A Challenge Throughout ECA Public Health Practice II.
Did you know... One in every six people on this globe suffers from a disease of poverty? One in every six people on this globe suffers from a disease.
4. Access to medication & healthcare Learning objectives: - to identify the why many people cannot access medication - to understand how NGOs and the UN.
Ensuring Humanitarian Access to Health-Related Technologies Wednesday, April 25, 2007 Bringing Hopkins to the Table.
SCI’s contribution to the global effort to control and eliminate schistosomiasis Dr Wendy Harrison 26 th June 2014.
Millions of people have a drug problem ! They can not get any !
Dreaded Diseases Schistosomiasis AIDS Virus Malaria Guinea Worm River Blindness.
Pharmaceuticals – a recap Discuss the view that “drugs companies are not fully addressing the needs of the world’s poorest people.”
TRIPS TRIPS is the Agreement on Trade Related Aspects of Intellectual Property Rights Framed within the WTO, by “consensus” Regulates intellectual property.
Sustainability: The R&D Pipeline for Neglected Disease Vaccines Elizabeth L. Ponder, PhD May 4, 2011 Global Vaccines 202X: Access, Equity, Ethics 2-4 May.
Donors, prize funds and patent pools. KEI & UNU- MERIT Maastricht Workshop on Medical Innovation Prizes January 28th-29th 2008 Michelle Childs, Head of.
Ellen ‘t Hoen Médecins sans Frontières
Issues related to poor IP protection in EMs: Pharmaceutical Example Rob May Commercial Director, Janssen, EMEA Emerging Markets.
International Trade Chapter #4.
Famine and Disease in Africa. Georgia Performance Standards SS7CG3 The student will analyze how politics in Africa impacts standard of living. b. Describe.
1 Economics of the Pharmaceutical Industry Prof. Brook K. Baker Northeastern University School of Law Health GAP (Global Access Project) UKZN – IP and.
THE TRANS-PACIFIC PARTNERSHIP An overview. History 2005: Trans-Pacific Strategic Economic Partnership Agreement, a free trade agreement, signed by Brunei,
Sudan represents many of the problems we see in Africa.
USAID Neglected Tropical Diseases Program. 2 WHO 17 Neglected Tropical Diseases (NTDs) by Strategic Interventions London Declaration 10 NTDs USAID 5 NTDs.
Research & development
World Health Organization
World Health Organization
Developing Drugs to Neglected Tropical Diseases
APPMG December 17, 2008 Presented by Dr. John P. Rumunu (MPH, MB.BS)
Where we could be by 2015 and how to get there
Penn’s Innovations and the Global Poor
Neglected Tropical Diseases Hidden and silent : Key problems
Neglected Tropical Diseases Hidden and silent : Key problems
Immunity to Infections – SPI XL –
Presentation transcript:

Did you know...  That one in every six people on this globe suffers from a disease of poverty?  That ten million people die each year from diseases that have available cures?  That, in the time it takes to read this slide, 5 people have died from preventable causes?

What is UAEM  Universities Allied for Essential Medicines  International organization  United States  Europe  Canada  Brazil  Works to construct creative, new approaches to improving the development and delivery of public health goods  Focuses on Neglected Tropical Diseases

National Objectives  to determine how universities can help ensure that biomedical end products, such as drugs, are made more accessible in poor countries and  to increase the amount of research conducted on neglected diseases, or those diseases predominantly affecting people who are too poor to constitute a market attractive to private-sector R&D investment.

Neglected Tropical Diseases  Buruli Ulcer  American Trypanosomiasis- Chagas Disease  Breakbone Fever- Dengue haemorrhagic fever  Guinea Worm Disease- Dracunculiasis  Fascioliasis  African Sleeping Sickness- Human African trypanosomiasis  Black Fever- Leishmaniasis  Leprosy  Elephantiasis- Lymphatic filariasis  Neglected zoonotic diseases  River Blindness- Onchocerciasis  Snail Fever- Schistosomiasis  Soil transmitted helminthiasis  Trachoma  Yaws

Why NTDs?  Called diseases of poverty  Generally in 3 rd world countries  Rich countries got rid of them long ago  Pharmaceutical companies have no financial gains  No money to be made means no new medicines developed

Patent Laws and Universities. When a University develops a drug, they sell rights to it via a license to a company. That company then patents the drug and has the only rights to produce it for a set number of years. This allows them to charge literally anything they want for profit. What can help? Global Access Policies with universities can allow the license to be accessible to generic companies as well as the big drug companies.

The d4t (stavudine) Story Scientists at Yale University discovered one of the first AIDS drugs, a molecule known as stavudine. Within a few years of its release, stavudine helped change HIV/AIDS from a rapid death sentence to a manageable condition. But stavudine was not reaching millions of desperately suffering people because they lacked the money to purchase it. Working with students on campus, Médecins Sans Frontières (MSF) urged Yale, as the patent-holder, to help increase access to the urgently needed drug. MSF’s request exploded into a student campaign that gave birth to Universities Allied for Essential Medicines.

The d4t (stavudine) Story Cont.   Yale and Bristol-Myers Squibb jointly announced that they would allow generic manufacturers of Stavudine to compete in certain markets, thus lowering the price of the drug from $15,000 per patient per year to just $55!

What is UAEM at CMU?  50 cents Campaign  Global Health Symposium  Health RSO Day  Global Access Week - Spring

Who can be a part of UAEM?  For ALL majors  Anything members want to focus on can be a goal of the organization  Chance to make a difference

What Can you Expect?  Biweekly meetings  Learn about other parts of the world  Work to raise money and educate people in the fights against tropical diseases  Have the chance to participate in a global movement  New organization = new ideas

“ There is no them, there is only us. ” Contact us at: Check out the National Website at: